Ureaplasma and Mycoplasma infections are caused by bacteria that live in the human urogenital tract, primarily spread through sexual contact. These organisms lack cell walls, making them resistant to common antibiotics like penicillin. They often cause no symptoms but can lead to infertility, pregnancy complications, and pelvic inflammatory disease.
These bacteria belong to the class Mollicutes, which includes species such as *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Mycoplasma hominis*, and *Mycoplasma genitalium*. They thrive in warm, moist environments and colonize mucosal surfaces of the reproductive and urinary tracts. Infection occurs when these microbes transfer from an infected partner during vaginal, anal, or oral sex.
According to the Centers for Disease Control and Prevention (CDC), *Mycoplasma genitalium* is linked to 10-20% of nongonococcal urethritis cases in men and is increasingly recognized as a cause of cervicitis and pelvic inflammatory disease in women. The American Society for Microbiology notes that these organisms are frequently misdiagnosed due to low sensitivity in standard urine tests.
Transmission occurs via direct contact with infected genital secretions. A single act of unprotected intercourse can transmit *Ureaplasma* or *Mycoplasma* if one partner is a carrier. The bacteria adhere to epithelial cells lining the urethra, cervix, or fallopian tubes, then multiply and trigger inflammation.
Once established, the infection may persist for months without noticeable signs. The immune system often fails to clear the organism completely because these bacteria evade detection by altering surface proteins. This allows them to remain dormant in tissues, leading to chronic or recurrent infections.
A 2021 study published in *Clinical Infectious Diseases* found that 30% of individuals diagnosed with *Mycoplasma genitalium* reported no prior symptoms. Among those who did, symptoms included mild dysuria (burning during urination), abnormal discharge, or lower abdominal pain-often dismissed as minor or unrelated.
Many people assume that all sexually transmitted infections (STIs) cause visible symptoms. That's not true for *Ureaplasma* and *Mycoplasma*. Up to 80% of infected individuals show no signs, creating a silent reservoir for transmission.
Another misconception is that these infections are rare. In reality, they're widespread. A 2020 surveillance report from the CDC showed that *Ureaplasma* was detected in 15% of routine STI screening samples from young adults aged 18-25. *Mycoplasma genitalium* prevalence is estimated at 1-2% in sexually active populations globally.
Testing is difficult because standard nucleic acid amplification tests (NAATs) used in clinics may miss low-level infections. Some labs use polymerase chain reaction (PCR) assays targeting specific genes like *mgc* in *M. genitalium*, but false negatives occur if sample collection is improper. The World Health Organization recommends using validated NAATs with proper specimen handling to improve accuracy.
The following table outlines the primary species involved, their typical sites of infection, and associated health risks:
| Bacterial Species | Primary Site of Infection | Associated Conditions |
|---|---|---|
| Ureaplasma urealyticum | Urethra, cervix, amniotic fluid | Non-gonococcal urethritis, premature birth, neonatal pneumonia |
| Ureaplasma parvum | Cervix, vagina | Chronic cervicitis, increased risk of preterm delivery |
| Mycoplasma hominis | Vagina, endometrium | Pelvic inflammatory disease, postpartum fever |
| Mycoplasma genitalium | Endocervix, urethra | Recurrent urethritis, infertility, ectopic pregnancy |
Among these, *Mycoplasma genitalium* is most concerning due to rising antibiotic resistance. A 2022 study in *The Lancet Infectious Diseases* reported that 30% of *M. genitalium* strains in Europe were resistant to azithromycin, the first-line treatment. This necessitates culture-based susceptibility testing in persistent cases.
In 2023, a 29-year-old woman presented with recurring pelvic pain and abnormal Pap smear results. She had tested negative for chlamydia and gonorrhea. After a repeat NAAT panel including *Mycoplasma genitalium*, she tested positive. Her partner, who had no symptoms, also tested positive.
Both were treated with moxifloxacin, a fluoroquinolone effective against resistant strains. Follow-up testing confirmed clearance. The case illustrates how asymptomatic carriers can sustain infection cycles and why partner treatment is essential.
One overlooked point is that carriage of *Ureaplasma* or *Mycoplasma* does not always equate to disease. Many healthy individuals harbor these organisms without harm. However, in immunocompromised people or those with existing reproductive conditions, colonization can progress to inflammation.
For example, *Ureaplasma* is commonly found in the vaginal flora of pregnant women. While usually harmless, it can ascend into the uterus and trigger preterm labor. A 2019 cohort study in *Obstetrics & Gynecology* found that women with *Ureaplasma* in amniotic fluid were five times more likely to deliver before 34 weeks.
Thus, detecting the organism is not enough-clinicians must assess clinical context. Treating asymptomatic carriers is not recommended unless they are planning pregnancy or have a history of adverse outcomes.
If you've had unprotected sex and experience unusual discharge, burning during urination, or pelvic discomfort, testing for *Ureaplasma* and *Mycoplasma* is warranted. Routine STI panels often exclude them, so request a specific test.
Antibiotics effective against these organisms include doxycycline, azithromycin, and moxifloxacin. However, resistance patterns vary by region. Always confirm treatment based on test results and partner status.
I once tested a patient with recurrent urinary tract symptoms unresponsive to standard antibiotics. Standard cultures were negative. Only after ordering a PCR panel for *Mycoplasma genitalium* did we identify the pathogen. After switching to moxifloxacin, symptoms resolved within seven days.
Understanding what causes ureaplasma and mycoplasma infections involves recognizing their stealth nature, diagnostic gaps, and the importance of targeted testing. These infections are not rare-they are underdiagnosed. Awareness leads to earlier intervention and better reproductive health outcomes.